RSV604 (A-60444) is a novel benzodiazepine derivative that acts as an inhibitor of respiratory syncytial virus (RSV), with an EC50 of 0.86 μM; it shows potential for the treatment of RSV-related diseases (Phase 2). It inhibits the growth of multiple RSV laboratory strains (RSS, Long, A2, and B) in plaque reduction assays (EC50: 0.5–0.9 μM); protects HEp-2 cells from RSV-induced cell death (EC50: 0.86 μM); reduces viral antigen synthesis in RSV-infected HEp-2 cells (EC50: 1.7 μM); and dose-dependently inhibits RSV infection in human airway epithelial (HAE) cells without significant cytotoxicity, disruption of epithelial barrier integrity, or alteration of ciliary beat frequency.